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associated with long-term mOCS use, and to quantify the cost and QALY burden 
of these events. Methods: A systematic review was undertaken to identify any 
studies reporting adverse event risk due to mOCS treatment. Seventy-two (72) stud-
ies were identified. The review focussed on eight disease outcomes representing 
the bulk of the mOCS cost and QALY burden: type II diabetes, myocardial infarc-
tion, glaucoma, cataract, ulcer, osteoporosis, infection, and stroke. A risk estimate 
for each adverse event was selected, based on the daily dose and mOCS exposure 
that best represented asthma-related mOCS use in Australian clinical practice. 
The excess risk of each complication in patients receiving mOCS, relative to those 
patients not receiving mOCS, was applied to the annual cost and QALY burden of 
each event in the Australian population. The cost and QALY burden attributable to 
mOCS was estimated on a per patient per year basis. Results: The expected annual 
cost of mOCS-related disease outcomes was estimated to be $598.32 per patient 
per year. Each patient treated with mOCS also suffers a QALY loss of 0.0367 per 
year of treatment. These effects are considered reversible once patients stop taking 
mOCS. ConClusions: mOCS are associated with a clear cost and QALY burden 
for patients with severe asthma which is likely underestimated by the approach 
adopted in this study. These results are likely to be useful for economic evaluations 
of new asthma interventions which replace or delay mOCS.
PRM35
CoMPaRing Cost-EffECtivEnEss of EMERging DRugs in aDvanCED 
CanCER Without hazaRD Ratios foR PRogREssion
Wiecek W, Karcher H
LASER Analytica, London, UK
objeCtives: To compare the cost-effectiveness via progression-free survival (PFS) for 
a new advanced cancer treatment (immuno-therapy A) against two active compara-
tors, both emerging drugs with publications reporting only their comparison against 
best supportive care (BSC) with progression-free survival curves, median survival and 
hazard ratios. Methods: PFS of therapy A compared to BSC could not be represented 
through a single hazard ratio (HR) estimates as progression hazards were obviously 
changing over the study course. Improvements in median PFS in all three studies 
were similar (2.5, 2.6, 2.6 months), while median PFS for BSC in three studies were: 5.0, 
6.7, 4.0 months. This highlighted the need for a meta-analysis to compare therapies. 
Instead of meta-analysing hazard ratios, the Ouwens method was applied to all six 
survival curves: (i) the curves were digitized and fitted to Weibull distributions, (ii) a 
fixed-effects model on shape and scale parameters was developed to deduce adjusted 
survival curves for the two comparators. Results: Two adjusted survival curves for 
comparator therapies were obtained and anchored to the control arm for therapy A. 
The areas under the adjusted PFS curves, with ratios 1.48 and 1.35 in favour of the new 
drug, were introduced in the cost-effectiveness model. ConClusions: The Ouwens 
method of meta-analysing progression-free survival curves was introduced into a 
cost-effectiveness model in advanced cancer. Meta-analysing not just the hazard ratio 
but a 2-parameter fit of the survival curves and adjusting survival curves accordingly 
enabled to build a cost effectiveness model in a situation where comparisons based 
on HR or on median survivals were not feasible.
PRM36
inCluDing huMan REsouRCE ConstRaints in hEalth EConoMiC 
Evaluations
Thongkong N, van Baal P, Severens JL
Erasmus University, Rotterdam, The Netherlands
objeCtives: Health economic evaluations mostly present decision makers results 
without taking local constraints into account. This might influence the actual use-
fulness of studies and, more importantly, result in suboptimal decisions. Human 
resource constraints have been recently raised as a constraint that is of particular 
importance, especially in low and middle income countries. This review article aims 
to explore to what extent human resource constraints are taken into account in 
economic evaluations. Methods: We conducted systematic literature review via 7 
electronic databases and then consulted some experts for additional relevant articles. 
We searched for articles that investigate economic evaluations and mention human 
resource constraints. Subsequently, these articles were classified based on to what 
extent they addressed human resource constraints. We distinguished the categories 
‘ignoring’, ‘dealing’ and ‘relaxing’ human resource constraints. Furthermore, we clas-
sified studies into modelling studies and studies based on primary data. Results: 
We found 200 articles, approximately. The findings show that 164 articles ignore the 
constraints, accounting for 88 and 76 articles of primary data use and modelling use, 
respectively. Only 32 articles deal with or relax the constraints. Of these articles, 27 
articles focus on the task shifting and the rest of them were distributed to the cat-
egories of dealing and relaxing, almost equally between modelling use and primary 
data use. ConClusions: Many cost effectiveness studies were conducted in settings 
in which human resource constraints are important. Although this is acknowledged, 
human resource constraints are often ignored in health economic evaluations. This 
practice results in biased estimates of the cost-effectiveness of interventions and 
misinforms decision makers. Guidance on how to properly deal with human resource 
constraints in cost-effectiveness analyses is needed.
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PUbLic HEALTH ExPERTiSE, Paris, France
objeCtives: Constructing a Markov model can be challenging as available data 
can be limited. In hepatitis C, more complex models that includes F0, F1, F2, F3 
and F4 fibrosis states are required by HTA agencies. However transition probabili-
ties (TP) can only be available for non-cirrhotic to cirrhotic states (simple model). 
Estimating separate TP for Fn to Fn+1 (Fn,n+1) can be challenging as Markov models 
are non-linear. The objective of this study was to estimate Fn,n+1 TP from a single 
non-cirrhotic (F0F3) to cirrhotic (F4) TP. Methods: Results in markov models are 
driven by sum of cycles spent in each state. Thus, the method was built to produce 
per minute for basic surgical procedure, excluding physician costs) were used to 
estimate potential savings. Results: There were a total of 239 cases: Cf= 118 and 
Rv= 121 patients. There were no significant differences between Cf and Rv patients 
in mean age, BMI, smoking status, diabetes, and prior radiation. Mean volume of 
fat harvested (499.5 vs 122.9 ml) and injected (178.9 vs 78.0 mL) were significantly 
higher (p< 0.0001) in the Rv group compared to the Cf group, respectively. Mean time 
to complete fat grafting was significantly shorter in the Rv group compared to the 
Cf group (35.3 vs 89.8 minutes, respectively; p< 0.0001). Mean OR costs with Rv were 
estimated to be $529-$706 vs $1347-$1796 with Cf. After taking into consideration 
the cost of Rv ($470), the potential net savings in mean OR costs were $347-$620 per 
case. ConClusions: The Rv fat processing system decreased operative time, which 
translated into a potential cost savings, and allowed for a larger volume of fat to be 
processed for injection compared to standard centrifugation.
PRM32
ConsistEnCy in sEaRCh stRatEgiEs foR systEMatiC litERatuRE 
REviEWs in niCE subMissions
Murphy D, Guy H, Hirst A
WG Access Ltd, London, UK
objeCtives: The NICE methods for technology appraisal require systematic litera-
ture reviews across clinical, cost-effectiveness, cost and resource use and health 
state utility values. These searches are a key component of a manufacturer sub-
mission. Whilst differences in population terms are expected across appraisals, 
this study reviewed search strategies submitted in three recent NICE appraisals 
to assess whether search terms used for methodological filters were consistent. 
The choice of databases searched were also reviewed. Methods: NICE technology 
appraisals were reviewed in reverse chronological order. Manufacturer submissions 
were searched to identify those that reported the search terms used. In order to 
keep the search manageable, a target of three papers was set in the first instance. 
Search terms for the following methodological filters were extracted: quality of 
life, cost and resource use, and cost-effectiveness. Results were compared quali-
tatively to assess the consistencies across search terms. Also extracted were the 
databases searched, presentation of search protocols and any Evidence Review 
Group (ERG) comments. Results: Search terms used for the methodological fil-
ters varied across submissions and similarly the databases searched differed. This 
was noted for all searches, with the comprehensiveness of searches differing across 
the three appraisals. In consideration of the presentation of search protocols, there 
was further variation resulting in lack of transparency. A common approach was 
to run a single search strategy for the cost-effectiveness and cost and resource 
use reviews. ConClusions: From this initial review there appears to be a lack of 
consistency in search terms included and databases searched in NICE technology 
appraisals. Whilst generic search filters are available there appears to be a need to 
drive awareness and application of these search terms. The implication for technol-
ogy appraisals is decision making based on non-optimized evidence bases.
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iDEntifiCation of itEMs foR a stanDaRDisED REsouRCE-usE MEasuRE: 
REviEW of CuRREnt instRuMEnts
Thorn JC1, Ridyard CH2, Riley R1, Brookes S1, Hughes D2, Wordsworth S3, Noble S1, 
Hollingworth W1
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objeCtives: To review the content of existing resource-use measures with a view 
to conducting a Delphi survey to identify core items that should be included in any 
UK trial-based economic evaluation. bACkgRound: Resource-use measurement 
by patient recall in economic evaluations alongside clinical trials is currently char-
acterised by inconsistency and a lack of validation. A fully validated standardised 
resource-use measure could potentially increase data quality, improve compara-
bility between cost-effectiveness analyses and reduce research burden on health 
economists. Methods: A single version of each instrument designed for use in 
a UK-based study was identified from the Database of Instruments for Resource-
Use Measurement (www.dirum.org). Section headings (‘domains’) and questions 
(‘items’) were extracted verbatim according to a predefined schema. Information 
on the recall period, level of detail, use of skip logic (i.e. a yes/no question designed 
to guide responders past irrelevant questions) and scope (disease-specific or total 
resource use) was also extracted. Items were scrutinised for overlap. Results: In 
excess of 2000 items were extracted from 59 instruments. The range of structures 
used to collect data was extremely wide, and varying levels of information were 
requested about similar items (for example, the number of hospital stays or the 
number of nights spent in hospital). Recall periods varied substantially (sometimes 
within an instrument), and total resource use was more commonly requested than 
disease-specific resource use. Skip logic was employed in over half the instruments 
reviewed. The original items were reduced to a list of 350 following preliminary 
scrutiny for overlap, and further reduced to approximately 60 key items for future 
inclusion in a Delphi survey of health economists.PReliMinARY ConClusions: 
There is substantial variation in the methods used to assess resource use in clini-
cal trials. Further work is in progress to prepare and administer the Delphi survey.
PRM34
Quantifying thE Cost anD Quality of lifE iMPliCations of aDvERsE 
EvEnts assoCiatED With long-tERM oRal CoRtiCostERoiD usE
Tilden D, Makino K, Cottrell S, Needham M
THEMA consulting Pty Ltd, Pyrmont, Australia
objeCtives: Maintenance oral corticosteroids (mOCS) are used in the treatment 
of severe asthma where patients have exhausted other available options with-
out achieving acceptable control of their symptoms. However, long-term mOCS 
is associated with the development of a number of serious adverse events. These 
complications cause considerable healthcare costs and quality-adjusted life year 
(QALY) losses. The aim of this study was to establish the excess risk of complications 
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threshold for cost-effectiveness. The objective of this research was to investigate 
the methodology used in public health modelling, to determine the effect that 
this has on predicted cost-effectiveness and to make recommendations about the 
most appropriate methods to use. Methods: We reviewed past NICE public health 
guidance and the associated economic evaluations to assess if methods tended 
to be based on the ICER alone or if other benefits are taken into account. In those 
instances where non-health benefits are included, we evaluated how this was done 
and if it was done consistently. Results: Results showed that a range of method-
ologies were used to evaluate public health interventions in the UK and that the 
methods used were inconsistent. ICERs were often calculated despite not always 
being the most appropriate measure. There tended to be considerable uncertainty 
around data inputs in the majority of economic evaluations. ConClusions: The 
methods used to evaluate public health interventions in the UK vary, mostly by the 
type of economic evaluation and the perspective taken. ICERs were not always the 
most appropriate outcome. Variations in the methods could result in inconsistent 
recommendations across Public Health Guidance.
PRM41
buDgEt iMPaCt analysis in thE uk sEtting – knoW youR auDiEnCE
Guy H, Lee A, Murphy D
WG Access Ltd, London, UK
objeCtives: When developing a budget impact model (BIM) the design stage is 
key. A particular element which should be carefully considered during the design 
phase is the perspective and in particular who the audience will be. The objec-
tive of this study was to identify who the potential users and healthcare decision-
makers may be and what elements should be captured within the BIM to meet their 
requirements within a UK setting. Methods: Research was conducted in a staged 
approach. The first stage involved identifying the different types of potential users 
of a BIM. Following identification of these different users, the next stage of research 
sought to identify the cost criteria each user is expected to assess a BIM against, thus 
informing what should be captured in an analysis. The final stage then identified 
what cost categories are required in a BIM to satisfy these criteria. Results: Two 
main users of a BIM were identified: providers and commissioners. The criteria that 
a provider is expected to consider is: what is the incremental cost and resource use 
implications of providing the intervention in question? What is the incremental 
income that will be received for providing this intervention? Whereas, the criteria 
that a commissioner is expected to consider are: what is the incremental cost of 
commissioning the provision of the intervention? Is there any added value in terms 
of quality, capacity or outcomes? An example of appropriate costs which are aligned 
with the perspective of a provider and commissioner, would be NHS reference costs 
and national tariffs, respectively. ConClusions: Determining the audience of a 
BIM is crucial in designing a model fit for purpose. Key requirements of a BIM will 
be dependent on the audience, in particular capturing costs appropriately. Research 
should be conducted for other countries.
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stRuCtuRE of hEalth-RElatED DiRECt Costs in ukRainE - thE fiRst stEP 
of analysis
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1Danylo Halytsky Lviv National Medical University, Lviv, Ukraine, 2Kyiv National Economic 
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objeCtives: Now in Ukraine state, regional and private budgets on country, 
regional, institutional and personal levels have substantial level of insufficiency. 
Human productivity is the main national asset for economic recovery, so, health 
care system could make significant impact and guarantee sustain economic 
growth. Therefore, every decision within Ukrainian healthcare system must be jus-
tified clinically and economically. With the purpose to prepare basis for economic 
justification the analysis of health-related cost categories specific for Ukraine was 
performed. Methods: Direct cost are specific for Ukrainian Healthcare system 
were drawn in 3 main categories: outpatient, inpatient and emergency (pre-hospi-
talization) costs. Macroeconomic result categories, Tax and Work policy, tariffs for 
services in healthcare system and standards for care were analyzed to determine 
cost units and cost compositions. Four payer perspectives were considered: state 
budget and funds; patient and family; employer; insurance company. Results: 
In result, health-related costs are specific for Ukraine and approaches for calcu-
lation were determined. Outpatient costs: outpatient visit costs (physician and 
nurse salary); diagnostic measures costs (laboratory or instrumental required by 
healthcare standards); treatment costs (basis or course required by healthcare 
standards). Inpatient costs: hospital-days costs (daily accommodation & care); 
diagnostic measures costs (laboratory or instrumental required by healthcare 
standards); treatment costs (single intake or course required by healthcare 
standards). Emergency costs: visit costs (physician and nurse salary); diagnostic 
measures costs (laboratory or instrumental required by healthcare standards); 
treatment costs (single intake required by healthcare standards); transportation 
costs (driver salary, fuel and amortization costs). ConClusions: Costs are drawn 
in current study to be validated internally in Ukraine with the State-Healthcare, 
Legislation, Economic experts. An external validation to be performed as well by 
the comparison of costs and cost categories with the same in other countries. 
After the validation, current cost matrix is planned to be integrated in population 
model for Cost of Illness Analysis.
PRM43
ConstRuCtion of siMulation tEChniQuEs foR DEvEloPMEnt of 
oPtiMal CERviCal CanCER sCREEning stRatEgiEs: ExPERiEnCE of 
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Soloviov S1, Artemchuk H1, Kovalyuk O1, Dzyublyk I1, Dutchak I2
1PL Shupyk National medical academy of postgraduate education, Kyiv, Ukraine, 2The National 
Technical University of Ukraine “Kyiv Polytechnic institute”, Kyiv, Ukraine
a similar number of cycles in the non-cirrhotic for both the simple and complex 
model. This was done by calculating: (1) the expected number of cycles in F0F3 
before transitioning to F4 (E) in the simple model; (2) the minimum number of cycles 
from Fn to F4 adjusted for the fibrosis stage distribution; (3) the (I-T)^-1 matrix equal 
to the average number of cycles in each Fn state based on (1) and (2); (4) the T matrix 
corresponding to the transition probability for Fn to Fn+1. Results: Based on a 
F0F3 to F4 TP of 0.04 and a fibrosis stage distribution of 23% F0 & F1, 27% F2 & F2, we 
obtained Fn to Fn+1 TP = 0.097. For both the simple and complex models E was equal 
to 25. However, the sum of cycles in the non-cirrhotic states after only 50 cycles 
were 20.12 and 21.92 for the simple and complex models respectively. Taking into 
account a 2% discounting the sums were 13.83 and 8.59. ConClusions: Markov 
models are sensitive to their structure, even when properly fitting the TP. For HCV, 
changing from a simple to a complex model is not trivial.
PRM38
thE Cost of tREatMEnt of thE nEW antiviRal thERaPiEs against thE 
hEPatitis C viRus
Kocsis T, Papp E, Nemeth B, Juhasz J
National institute of Pharmacy and Nutrition, budapest, Hungary
objeCtives: The goal of our poster is to analyse the costs of treatment of the 
new antiviral therapies against the Hepatitis C virus (HCV) submitted to the 
Department of Health Technology Assessment of the National Institute of 
Pharmacy and Nutrition. Methods: In our analysis, we examined the cost of 
treatment with the available interferon (IFN)-based and IFN-free therapies based 
on the current PUPHA database from the official website of National Health 
Insurance Fund of Hungary. The cost estimates have been made in two different 
ways both from the payer’s view. The first calculation does not take into account 
the success of therapy as it’s based on the SPC with the assumption of a com-
plete possible length of the treatment. The second calculation method is based 
on the sustained virologic response (SVR) which has become the best indication 
of therapeutic success. Results: Performance-based risk-sharing arrangements 
should be based on an endpoint which is meaningful both from the payer’s and 
the patients’ perspective, which can be measured objectively and which depends 
primarily on the applied therapy. This endpoint is the SVR rate in the treatment of 
HCV. The SVR rates were between 34,4% and 95% in the relevant clinical studies. 
The cost of the therapy ranges between 8.4 million HUF and 31 million HUF, if we 
do not take into account the SVR rates. ConClusions: Following a more than 
two decades of intense research, the interferon-free era of hepatitis C treatment 
has arrived. The availability of IFN-free regimens allows many patients who could 
not be treated previously because of medical or psychiatric contraindications or 
an inability to tolerate IFN to receive treatment. Introduction of these new HCV 
drugs put a financial strain on the payer. The use of performance-based financing 
is a way to maintain the balance of the budget.
PRM39
REsouRCE usE MEasuREMEnt in tRials ConDuCtED in CaRE hoMEs: 
a stuDy of lEvEl-of-agREEMEnt bEtWEEn Data CollECtED fRoM gP 
RECoRDs anD CaRE hoME RECoRDs
Sach T1, Desborough J1, Houghton J2, Holland R2
1University of East Anglia, Norwich, UK, 2University of East anglia, Norwich, UK
objeCtives: Methodological research focused on resource use measurement has 
been limited in comparison to the amount of research focussed on measuring out-
comes within the economic evaluation context. This study was designed to assess 
the level-of-agreement between two different sources of health and social care 
resource use data collected on care home residents. Methods: The methods were 
informed by a review of level-of-agreement studies concerned with resource use 
in older people. In the base case, resource use data collected from both GP medical 
records (electronic records) and care home records (paper-based records) on 362 
care home residents were obtained as part of the CAREMED cluster randomised 
controlled trial. Descriptive statistics were explored before assessing level-of-agree-
ment through percent agreement, 95% limits of agreement, and Lin’s concordance 
correlation coefficient (CCC). Sensitivity analyses excluded non-users and tested 
timeframe. Factors affecting the magnitude of difference were explored using multi-
level modelling. Results: Several resource items (number of GP, out of hours GP 
and podiatrist contacts) were found to have substantial agreement (0.61 to 0.80) 
between the GP records and care home records according to the CCC. The number of 
total visits, dietician, paramedic and SLT contacts showed moderate agreement (0.41 
to 0.60). Most resources showed a poor (less than 0.00) or slight (0.00 to 0.22) level-
of-agreement either due to care home records (for chiropodist, music therapy, and 
social worker contacts) or GP records (for phlebotomist and practice nurse) record-
ing a greater number of visits. Patient classification (residential/nursing), number 
of falls, number of STOPP criteria met, number of medications and comorbidities 
significantly affected the magnitude of differences observed. ConClusions: This 
research suggests that both sources of data are reliable for some resources but 
not others, indicating dual sources may be necessary where a wider perspective is 
important and feasible in terms of costs of data collection.
PRM40
aRE Qalys an aPPRoPRiatE MEasuRE to usE WhEn Evaluating PubliC 
hEalth intERvEntions in thE uk?
Taylor M, Filby A
York Health Economics consortium, York, UK
objeCtives: Quality-adjusted life years (QALYs) are commonly used in health tech-
nology appraisals, including those by NICE in the UK. However, QALYs only include 
‘health-related’ quality of life (QOL) which may not apply to interventions that 
have benefits and costs that fall outside of the NHS. NICE recommends that public 
health economic evaluations take a cost consequence or cost benefit approach 
and present a public sector or societal perspective. However, it is not clear how or 
if the costs and benefits that fall outside the NHS should be incorporated into this 
